articleTop 1% cited
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2008 · Vol. 26(21) · pp. 3543–3551
Giorgio V. Scagliotti✉Purvish ParikhJoachim von PawelBonne BiesmaJohan VansteenkisteChristian ManegoldPiotr SerwatowskiU. GatzemeierRaghunadharao DigumartiMauro ZukinJin S. LeeAnders MellemgaardKeunchil ParkShehkar PatilJanusz RolskiTuncay GökselFilippo de Marinis(European Institute of Oncology)Lorinda SimmsKatherine P. SugarmanDavid R. Gandara
Abstract
In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. This is the first prospective phase III study in NSCLC to show survival differences based on histologic type.
Lung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and TreatmentPemetrexedGemcitabineMedicineCisplatinInternal medicineNeutropeniaLung cancerFebrile neutropeniaOncologyChemotherapy
MeSH terms
PemetrexedGemcitabineAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineFemaleGlutamatesGuanineHumansLung NeoplasmsMaleMiddle AgedKaplan-Meier Estimate
Citations
3,206
FWCI
183.52
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Cited by
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Mechanisms of Resistance to Crizotinib in Patients with <i>ALK</i> Gene Rearranged Non–Small Cell Lung Cancer
Clinical Cancer Research · 2012 · 1,061 citations
Establishing the Diagnosis of Lung Cancer
CHEST Journal · 2013 · 1,052 citations
Exploratory Study to Identify Radiomics Classifiers for Lung Cancer Histology
Frontiers in Oncology · 2016 · 369 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 2,268 citations
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2012 · 928 citations
References
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
Biometrics · 1975 · 2,349 citations
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Journal of Clinical Oncology · 2004 · 1,949 citations
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Journal of Clinical Oncology · 2003 · 3,045 citations
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Journal of Clinical Oncology · 2004 · 2,425 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Nonparametric Estimation from Incomplete Observations
Journal of the American Statistical Association · 1958 · 38,793 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.